treatment with ganciclovir combined with immune globulin, it remains an important cause of morbidity and mortality after allogeneic BMT.
242
biweekly during the first 4 months after transplantation. The
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CMV antigenemia assay was performed according to the Myelodysplastic syndrome 3 2 1 method described previously. 16 In brief, blood leukocytes Definitive of CMV-associated disease BU = busulfan; CY = cyclophosphamide; Ara-C = cytosine arabinoside; G-CSF + Ara-C = Ara-C combined with G-CSF; VP16 = etoposide; TBI = total body irradiation; CSP = cyclosporine; MTX = methotrexate;
Active CMV infection was defined as the detection of CMV ATG = antithymocyte globulin.
antigen-positive cells (у1/50 000 WBCs), isolation of a Other regimens included BU/VP16 1, BU/CY/Ara-C 1, BU/CY/TLI (total CMV and/or seroconversion or a significant rise of IgG lymphoid irradiation) 1, CY/TLI 1, TBI/G-CSF + Ara-C 1, TBI/CY/G-CSF + Ara-C 1, and TBI/Melphalan 1.
antibodies. CMV-associated disease was defined as the presence of at least two of the following signs with active CMV infection; unexplained fever for 3 or more days, leukopenia, thrombocytopenia, atypical lymphocytosis, hepamolecularly at class II loci. All patients were CMV-seropositive before BMT. Patient characteristics are shown in titis, gastrointestinal bleeding or ulceration, interstitial pneumonia, typical retinitis, or nephropathy. 26,27 For CMV- Table 1 . All patients achieved sustained engraftment and 85% of patients survived for more than 100 days after transassociated disease, CMV pneumonia was diagnosed based on pulmonary symptoms such as cough and dyspnea, interplantation.
stitial infiltrates, and a positive CMV culture or characteristic cells with intranuclear inclusion bodies from bronchoBone marrow transplantation alveolar lavage fluid specimens. CMV enteritis was histologically proven. [4] [5] [6] [7] [8] Regimens for pretransplant conditioning are shown in Table 1 . Total body irradiation (TBI)-, or total lymphoid irradiation (TLI)-containing regimens was used in UD-BMT, while busulfan/cyclophosphamide regimen in Statistical analysis addition to TBI-containing regimens were used in related donor BMT.
For the prevention of acute GVHD, patients were given Statistical analysis was performed using Fisher's exact test, or nonparametric Kruskal-Wallis test, as indicated. A P cyclosporine combined with methotrexate and/or antithymocyte globulin (ATG), cyclosporine alone, methotrexate value of Ͻ0.05 was accepted as statistically significant. The actuarial probability of acquiring CMV infection or CMValone, or FK506 combined with methotrexate according to the Seattle protocol, with minor modifications. 21, 22 Acute associated disease was determined by Kaplan-Meier plots and analyzed by a log-rank test. GVHD was diagnosed using the clinical criteria described Table 2 Incidence of CMV antigenemia and CMV-associated disease 53% in the former group and 87% in the latter group according to bone marrow donor (P Ͻ 0.01). Similarly, the probability of developing CMVassociated disease was significantly lower in patients who (median time) post-transplant in sibling donor BMT, in contrast to 5 weeks in UD-BMT (P Ͻ 0.05). The peak levels of CMV antigen-positive leukocytes were significantly higher in patients with CMV-associated disease than in those with asymptomatic infection in both related and unrelated donor BMT (the median number of CMV antigenpositive cells per 50 000 WBCs: 22 vs 2, P Ͻ 0.01). The different conditioning regimens including with or without TBI did not affect the incidence of CMV infection and CMV-associated disease. The peak levels of CMV antigenemia during the period of monitoring in 72 patients are shown in Figure 3 , according Results
Incidence of CMV antigenemia and CMV-associated disease
CMV antigenemia was detected in 41 of 72 patients (57%) during the period of monitoring, between 3 and 18 weeks after transplantation (Table 2) . CMV-associated disease developed in 20 of 72 patients (28%), which comprised 49% of the patients with positive antigenemia. CMV antigenemia was detected in all patients who developed CMVassociated disease. The probabilities of acquiring CMV infection and CMV-associated disease in patients who received marrow from HLA-identical sibling donors and HLA-matched unrelated donors are shown in ease; *, P Ͻ 0.01 by nonparametric Kruskal-Wallis statistics.
to the type of bone marrow donors. The levels of CMV ganciclovir (10 mg/kg/day) immediately after the onset of disease. Treatment with ganciclovir was highly effective antigenemia were significantly higher in UD-BMT (16 CMV antigen-positive cells per 50 000 WBCs) than in in reducing the levels of CMV antigenemia in sibling donor transplant patients, compared with unrelated donor HLA-identical sibling donor BMT (one cell) or one locus HLA-mismatched related (no cell) donor BMT; the differtransplant patients. The clinical symptoms of disease disappeared along with a rapid decrease in the number of ences between UD-BMT and related donor BMT were significant (P Ͻ 0.01). The incidence of CMV-associated CMV antigen-positive cells. CMV antigen-positive cells decreased below 50% of the pretreatment levels within 2 disease was significantly higher in patients with CMV antigen-positive cells in excess of 10 per 50 000 cells (17 weeks after ganciclovir treatment in six of seven sibling donor transplant patients (86%), and in seven of 11 unreof 20 patients, 85%) than in patients with less than 10 per 50 000 cells positive (three of 21 patients, 14%) or those lated donor transplant patients (63%). These differences did not reach statistical significance. without CMV antigenemia (0 of 31 patients) (Figure 3 , P Ͻ 0.05).
Relationship between CMV antigenemia and acute GVHD First detection of CMV antigenemia: timing and level
Acute GVHD developed in 18 of 49 patients (37%) transplanted from HLA-identical sibling donors, in four of eight Timing of the first detection of CMV antigenemia and the number of antigen-positive cells is shown in Figure 4 . The patients (50%) transplanted from mismatched related donors, and in 10 of 15 patients (67%) transplanted from time from transplantation to first detection of CMV antigenpositive cells was comparable in UD-BMT and sibling unrelated donors. The relationship between the incidence of positive CMV antigenemia or CMV-associated disease donor BMT (5 weeks vs 6 weeks after BMT). However, the number of CMV antigen-positive cells at the first detecand the grade of acute GVHD is shown in Table 3 . In HLAidentical sibling donor BMT, the development of acute tion was significantly higher in UD-BMT than in sibling donor BMT (the median number of CMV antigen-positive GVHD was associated with an increased incidence of positive CMV antigenemia and CMV-associated disease: CMV cells per 50 000 WBCs: 15 vs 1, P Ͻ 0.01). In nine of 11 unrelated donor transplant patients, CMV antigenemia antigenemia was positive in 72% of patients who developed acute GHVD, and in 42% of patients who did not became positive at the onset of CMV-associated disease.
(P Ͻ 0.05). CMV-associated disease developed in 28% of patients with acute GVHD, and in 7% of patients without CMV antigenemia before and after the onset of CMVacute GVHD (P Ͻ 0.05). The maximum number of CMV associated disease antigen-positive cells also correlated with the grade of acute GVHD in sibling donor transplant patients; 0/50 000 WBCs The levels of CMV antigenemia were analyzed before the onset of CMV-associated disease and after treatment with in patients without GHVD, 2/50 000 WBCs in patients with grade I GVHD, and 21/50 000 WBCs in patients with grade ganciclovir in 18 patients with CMV-associated disease, including seven sibling donor and 11 unrelated donor trans-II-IV GVHD (Figure 6 ). On the other hand, in unrelated donor transplant patients, neither the incidence of CMV plant patients ( Figure 5 ). CMV antigenemia became positive 1 week (median time) before the onset of CMV-assoinfection and CMV-associated disease nor the level of CMV antigenemia correlated with the grade of acute ciated disease in sibling donor transplant patients, whereas CMV antigen-positive cells were detected at the onset of GVHD (Table 3 , Figure 6 ). The administration of у250 mg/day of methylpredniso-CMV-associated disease in unrelated donor transplant patients (P Ͻ 0.05). Positive CMV antigenemia preceded lone (mPSL) for 3 days or more for the treatment of acute GVHD did not significantly affect the incidence of CMV CMV-associated disease in five of seven sibling donor transplant patients (71%), in contrast to two of 11 unrelated infection and CMV-associated disease, although the peak level of CMV antigenemia were higher in patients receiving donor transplant patients (28%) (P Ͻ 0.05).
All patients with CMV-associated disease received mPSL than in those not receiving mPSL (data not shown).
In UD-BMT, five of 15 patients were given ATG for prophylaxis against acute GVHD. However, the administration of ATG did not affect the incidence of CMV infection and CMV-associated disease.
Discussion
The present study demonstrated a higher incidence of CMV infection and CMV-associated disease in patients transplanted with marrow from unrelated donors than in those transplanted with marrow from HLA-identical sibling donors. One possible explanation is that this higher inci- dence may be due to the increased incidence and severity because the development of acute GVHD is one of the 
Onset
Weeks before and after the onset of CMV-associated disease major risk factors for CMV-associated disease after allociated disease. Accordingly, the relationship between GVHD and CMV-associated disease should be elucidated geneic BMT. 1, 7, 8 The precise mechanism for the effect of acute GVHD on the development of CMV-associated disto prevent CMV-associated disease after BMT. The increased incidence of CMV infection and CMVease remains unknown. CMV-specific cytotoxic T lymphocytes (CTL) are considered to play an important role in the associated disease was observed in unrelated donor transplant patients even in those without acute GVHD, comcontrol of CMV infection. It has been reported that the growth of this CTL population is impaired in patients who pared with those who received related donor BMT. CMVassociated disease has been reported to be less common in develop acute GVHD. 8 This may be related to the reactivation of CMV and the subsequent occurrence of CMVpatients with syngeneic or autologous BMT. 28, 29 Moreover, in vivo and in vitro studies have revealed that alloantigenic associated disease in patients with acute GVHD. Our data also showed that the prophylactic use of ATG and the treatstimulation facilitates the reactivation of CMV from lymphocytes. [30] [31] [32] Genetic disparity is greater in BMT from ment of acute GVHD with high-dose mPSL did not increase the incidence of CMV infection and CMV-associaphenotypically HLA-identical unrelated donors than from genotypically HLA-identical sibling donors. 10, [33] [34] [35] These ted disease. This suggests that the immunosuppressive effects associated with acute GVHD may be more critical observations suggest that alloantigen stimulation by unknown or undefined histocompatibility antigens may be than those associated with ATG or high-dose mPSL treatment once CMV-associated disease develops. Furthermore, another important factor affecting the incidence of CMV infection and CMV-associated disease in UD-BMT. TBI-containing regimens for pretransplant conditioning did not affect the incidence of CMV infection and CMV-assoAnother possible explanation is that donor T cells in UD- BMT may be incapable of efficiently eliminating CMV immunocompetence may be profoundly suppressed in unrelated donor transplant patients. Similarly, their incidence from host cells because of incomplete recognition of CMV antigens presented by host HLA due to HLA disparity and CMV antigenemia level in patients who received transplants from unrelated donors were also significantly higher between donor and recipient. Although the increased incidence of CMV-associated disease was observed in UDthan in those who received transplants from one-locus HLA-mismatched related donors, suggesting that there may BMT, the incidence of serious CMV-associated disease, including CMV-IP and CMV enteritis, were comparable for be a difference in the degree of alloantigenic stimulation between these two groups. This result may offer helpful related and unrelated donor transplants in this study. The reason remains unknown and further study is required to information in the choice of either related or unrelated bone marrow donors, although the overall survival after BMT confirm this finding.
The sensitivity and specificity of the CMV antigenemia has been reported to be comparable in these two groups. 10, 38 Thus, one locus HLA-mismatched related donors would be assay exceeded 90% in the detection of active CMV infection. The level of CMV antigenemia is expressed quantitatselected preferentially compared to unrelated donors, to minimize the incidence of CMV-associated disease after ively and is reported to correlate with the severity of symptoms.
14-17 Boeckh et al 15 have demonstrated that a BMT. It has been demonstrated that CMV antigen-positive cells significantly higher number of CMV antigen-positive cells was observed in BMT patients with CMV pneumonia or can be detected from several days to 1 week before the onset of CMV-associated disease after an organ transplant CMV enteritis than in patients with antigenemia alone. 15 It has been shown in organ transplant patients that a relatively including kidney, heart, or liver. 14,17,18 We have also shown that CMV antigen-positive cells become detectable from 1 high number of CMV antigen-positive cells may correlate with the development of symptomatic CMV infection. 18 to 4 weeks before the onset of CMV-associated disease after BMT from HLA-identical sibling donors. 16 These Moreover, patients with Ͼ10 CMV antigen-positive cells/50 000 WBCs subsequently developed CMV-associaobservations indicate that positive CMV antigenemia is a useful marker for the prediction of subsequent CMV-assoted disease in renal transplantation, 26 Ͼ50/50 000 WBCs in liver transplantation, 36 and Ͼ100/50 000 WBCs in heart ciated disease. However, Koehler et al 39 questioned the predictive value of CMV antigenemia in the BMT setting, transplantation. 17 In this study, 10/50 000 WBCs appeared to be a significant level of CMV antigenemia for the compared with that in organ transplantation. This discrepancy might be explained by a difference in the degree of diagnosis of CMV-associated disease in the setting of allogeneic BMT, as shown previously. 16 diversity of histocompatibility antigens between the donor population in the United States and Japan, as suggested by The level of antigenemia is reported to be inversely correlated with the host immunocompetence.
26,27,37 In our our results with positive antigenemia being less predictive in UD-BMT than in related donor BMT. The incidence and study, the peak levels of CMV antigenemia were increased in unrelated donor transplant patients. Moreover, it was severity of acute GVHD are also lower in Japan than in the United States, probably due to the genetic homogeneity observed that CMV antigen-positive cells did not disappear rapidly after ganciclovir treatment in unrelated donor transof the Japanese population. 22, 40, 41 The lower degree of HLA diversity probably leads to lower alloantigenic stimulation, plant patients, as compared with HLA-identical sibling donor transplant patients. These results suggest that host which results in a decreased incidence of CMV infection 
